Humanigen Inc. (HGEN) Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
April 9, 2021 7:00 AM EDTPhase 1 dose escalation and bioimaging study shows that ifabotuzumab demonstrates highly specific tumor targeting in patients with recurrent glioblastoma multiforme Results to be presented as a virtual poster at American Association for Cancer Research (AACR) 2021 Annual Meeting
BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered® antibody, ifabotuzumab, in patients with glioblastoma multiforme... More
